Tiffany A. Traina

13.1k citations

146 papers · 4.0k indexed · 2 hit papers · h-index 30

Impact in

Cancer Research top 1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy

Papers in

Oncology 107
- Cancer Treatment and Pharmacology 53
- HER2/EGFR in Cancer Research 43
- PARP inhibition in cancer therapy 19
Cancer Research 47
- Breast Cancer Treatment Studies 36
- Cancer Genomics and Diagnostics 14

Co-authors: Ayca Gucalp Clifford A. Hudis Sujata Patil Larry Norton William L. Gerald Eric P. Winer Karen A. Cadoo Hope S. Rugo
Journals: Journal of Clinical Oncology (53 papers)Cancer Research (14 papers)Breast Cancer Research and Treatment (11 papers)Clinical Breast Cancer (7 papers)Clinical Cancer Research (6 papers)
Partner nations: United States United Kingdom Singapore

In The Last Decade

Tiffany A. Traina

136 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer 2018 · 348 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2018 Breast Cancer Research and Treatment

Peers

Countries citing papers authored by Tiffany A. Traina

Since Specialization

Citations

This map shows the geographic impact of Tiffany A. Traina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiffany A. Traina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiffany A. Traina more than expected).

Fields of papers citing papers by Tiffany A. Traina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tiffany A. Traina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiffany A. Traina. The network helps show where Tiffany A. Traina may publish in the future.

Co-authors

The 25 scholars most cited alongside Tiffany A. Traina, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tiffany A. Traina Line = papers co-authored together Tiffany A. Traina links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction. Journal of Clinical Oncology ·Sherry Shen, Verna Solomon, Dominiq Williams, Mark E. Robson, Larry Norton, Tiffany A. Traina, Neil M. Iyengar	2023	1
2	4MO Homologous recombination (HR) status of platinum-responsive advanced triple-negative breast cancers (aTNBC) treated with olaparib as maintenance therapy ESMO Open ·Tira J. Tan, Sarah Sammons, J. Lynn Fink, Whee Sze Ong, Binny Jaradi, Paul Waring, Yong Sheng Jason Chan, X.P. Lee, B.Y. Lim, Jeff Brady, Andrew B. Nixon, Tiffany A. Traina, Carey K. Anders, S-B. Kim, Y-H Im, Rebecca Dent	2023	1
3	Abstract OT1-03-05: TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who are not candidates for anti-PD-(L)1 therapy Cancer Research ·Rebecca Dent, David W. Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A. Traina, Petra Vuković, Darlington Mapiye, Micah J. Maxwell, Peter Schmid, Javier Cortés	2023	4
4	Homologous recombination–deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants Proceedings of the National Academy of Sciences ·Rohit Prakash, Yashpal Rawal, Meghan R. Sullivan, McKenzie K. Grundy, Hélène Bret, Michael J. Mihalevic, Hayley L. Rein, Jared M. Baird, Kristie Darrah, Fang Zhang, Raymond Wang, Tiffany A. Traina, Marc R. Radke, Scott H. Kaufmann, Elizabeth M. Swisher, Raphaël Guérois, Mauro Modesti, Patrick Sung, Maria Jasin, Kara A. Bernstein	2022	17
5	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer Clinical Cancer Research ·Siang‐Boon Koh, Kenneth N. Ross, Steven J. Isakoff, Nsan Melkonjan, Lei He, Karina J. Matissek, Andrew Schultz, Erica L. Mayer, Tiffany A. Traina, Lisa A. Carey, Hope S. Rugo, Minetta C. Liu, Vered Stearns, Adam Langenbucher, Srinivas Vinod Saladi, Sridhar Ramaswamy, Michael S. Lawrence, Leif W. Ellisen	2021	16
6	Initial encoding deficits with intact memory retention in older long-term breast cancer survivors Journal of Cancer Survivorship ·Alexandra M. Gaynor, Tim A. Ahles, Elizabeth Ryan, Elizabeth Schofield, Yuelin Li, Sunita K. Patel, Katrazyna McNeal, Tiffany A. Traina, James C. Root	2021	6
7	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG) Clinical Breast Cancer ·Muaiad Kittaneh, Sunil Badve, Humberto Caldera, Robert E. Coleman, Matthew P. Goetz, Reshma Mahtani, Eleftherios P. Mamounas, Kevin Kalinsky, Elyse E. Lower, Mark D. Pegram, Michael F. Press, Hope S. Rugo, Lee S. Schwartzberg, Tiffany A. Traina, Charles L. Vogel	2020	12
8	Multigene assays in early breast cancer: Insights from recent phase 3 studies European Journal of Surgical Oncology ·Christos Markopoulos, David M. Hyams, Henry Gómez, Mark Harries, Seigo Nakamura, Tiffany A. Traina, Artur Katz	2019	20
9	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) Breast Cancer Research and Treatment ·Jame Abraham, Humberto Caldera, Robert E. Coleman, Anthony Elias, Matthew P. Goetz, Muaiad Kittaneh, Elyse E. Lower, Reshma Mahtani, E. Mamounas, Mark D. Pegram, Hope S. Rugo, Lee S. Schwartzberg, Tiffany A. Traina, Chuck Vogel	2018	9
10	A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer Clinical Cancer Research ·Lee S. Schwartzberg, Denise A. Yardley, Anthony Elias, Manish R. Patel, Patricia LoRusso, Howard A. Burris, Ayca Gucalp, Amy Peterson, Martha Blaney, Joyce Steinberg, Jacqueline A. Gibbons, Tiffany A. Traina	2017	42
11	Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review npj Breast Cancer ·Karen A. Cadoo, Devika Gajria, Emily K. Suh, Sujata Patil, Maria Theodoulou, Larry Norton, Clifford A. Hudis, Tiffany A. Traina	2016	8
12	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019 Clinical Cancer Research ·Costanza Paoletti, Yufeng Li, Maria C. Muñiz, Kelley M. Kidwell, Kimberly Aung, Dafydd G. Thomas, Martha E. Brown, Vandana G. Abramson, William Irvin, Nancy U. Lin, Minetta C. Liu, Rita Nanda, Julie R. Nangia, Anna Maria Storniolo, Tiffany A. Traina, Christos Vaklavas, Catherine Van Poznak, Antonio C. Wolff, Andres Forero‐Torres, Daniel F. Hayes	2015	75
13	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer Clinical Breast Cancer ·Neil M. Iyengar, Monica Fornier, Steven Sugarman, Maria Theodoulou, Tiffany A. Troso-Sandoval, Gabriella D’Andrea, Pamela Drullinsky, Devika Gajria, Shari Goldfarb, Elizabeth Comen, Diana Lake, Shanu Modi, Tiffany A. Traina, Mario E. Lacouture, Melanie F. Chen, Sujata Patil, José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang	2015	2
14	Tolerability of Chemotherapy in HIV-Infected Women with Breast Cancer: Are There Prognostic Implications? AIDS Patient Care and STDs ·Lalitha Parameswaran, Ying Taur, Monika K. Shah, Tiffany A. Traina, Susan K. Seo	2014	17
15	The Role of the Androgen Receptor in Triple-Negative Breast Cancer Women s Health ·Payal Shah, Ayca Gucalp, Tiffany A. Traina	2013	97
16	The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer The American Journal of Surgery ·Matthew Pugliese, Michelle Stempel, Sujata Patil, Meier Hsu, Alice Y. Ho, Tiffany A. Traina, Monica Morrow, Hiram S. Cody, Mary L. Gemignani	2010	10
17	Triple-Negative Breast Cancer The Cancer Journal ·Ayca Gucalp, Tiffany A. Traina	2010	107
18	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer Clinical Cancer Research ·Kevin Kalinsky, Lindsay M. Jacks, Adriana Heguy, Sujata Patil, Marija Drobnjak, Umesh Bhanot, Cyrus V. Hedvat, Tiffany A. Traina, David B. Solit, William L. Gerald, Mary Ellen Moynahan	2009	299
19	Targeting insulin-like growth factor type 1 receptor in cancer therapy Targeted Oncology ·Francesco Atzori, Tiffany A. Traina, Maria Teresa Ionta, B. Massidda	2009	35
20	Bevacizumab for Advanced Breast Cancer Hematology/Oncology Clinics of North America ·Tiffany A. Traina, Hope S. Rugo, Maura N. Dickler	2007	23

About Tiffany A. Traina

Tiffany A. Traina is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Genetics, having authored 146 papers that have together received 4.0k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (54 papers), Cancer Treatment and Pharmacology (53 papers), HER2/EGFR in Cancer Research (43 papers), Breast Cancer Treatment Studies (36 papers), Estrogen and related hormone effects (19 papers), PARP inhibition in cancer therapy (19 papers), Prostate Cancer Treatment and Research (16 papers) and Cancer Genomics and Diagnostics (14 papers). The work is most often cited by research in Cancer Research (1.6k citations), Oncology (2.4k citations), Pulmonary and Respiratory Medicine (1.4k citations), Genetics (698 citations) and Genetics (251 citations). Tiffany A. Traina has collaborated with scholars based in United States, United Kingdom and Singapore. Frequent co-authors include Ayca Gucalp, Clifford A. Hudis, Sujata Patil, Larry Norton, William L. Gerald, Eric P. Winer, Karen A. Cadoo, Hope S. Rugo, Kevin Kalinsky and Anthony Elias. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Clinical Breast Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact